CA2537230A1 - Use of pde4 inhibitors for the treatment of diabetes mellitus - Google Patents

Use of pde4 inhibitors for the treatment of diabetes mellitus Download PDF

Info

Publication number
CA2537230A1
CA2537230A1 CA002537230A CA2537230A CA2537230A1 CA 2537230 A1 CA2537230 A1 CA 2537230A1 CA 002537230 A CA002537230 A CA 002537230A CA 2537230 A CA2537230 A CA 2537230A CA 2537230 A1 CA2537230 A1 CA 2537230A1
Authority
CA
Canada
Prior art keywords
dimethoxy
cis
hexahydrophenanthridine
phenyl
phthalazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002537230A
Other languages
English (en)
French (fr)
Inventor
Hans-Peter Kley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma Ag
Hans-Peter Kley
Nycomed Gmbh
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Hans-Peter Kley, Nycomed Gmbh, Takeda Gmbh filed Critical Altana Pharma Ag
Publication of CA2537230A1 publication Critical patent/CA2537230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
CA002537230A 2003-09-05 2004-09-02 Use of pde4 inhibitors for the treatment of diabetes mellitus Abandoned CA2537230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03020126.3 2003-09-05
EP03020126 2003-09-05
PCT/EP2004/052005 WO2005023253A1 (en) 2003-09-05 2004-09-02 Use of pde4 inhibitors for the treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
CA2537230A1 true CA2537230A1 (en) 2005-03-17

Family

ID=34259164

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002537230A Abandoned CA2537230A1 (en) 2003-09-05 2004-09-02 Use of pde4 inhibitors for the treatment of diabetes mellitus

Country Status (6)

Country Link
US (1) US7776893B2 (enI)
JP (1) JP2007504201A (enI)
AU (1) AU2004269923B2 (enI)
CA (1) CA2537230A1 (enI)
MX (1) MXPA06002521A (enI)
WO (1) WO2005023253A1 (enI)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101302838B1 (ko) 2005-03-08 2013-09-03 다케다 게엠베하 진성 당뇨병 치료용 로플루밀라스트
MEP8509A (en) * 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2014124860A1 (en) * 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
JP2015067538A (ja) * 2013-09-26 2015-04-13 株式会社アイエイアイ 血糖値降下剤

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
IL106517A0 (en) 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
JPH08509203A (ja) * 1992-10-15 1996-10-01 ダナ−ファーバー キャンサー インステテュート インコーポレイテッド ＴＮＦ−α作用の拮抗剤を用いる肥満関連糖尿病▲ＩＩ▼型のインスリン耐性の治療
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
CN1043993C (zh) * 1994-08-29 1999-07-07 山之内制药株式会社 萘啶衍生物及其医药组合物
JP4138003B2 (ja) * 1996-01-31 2008-08-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のフェナントリジン
DE19617864A1 (de) * 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
ATE273996T1 (de) * 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
WO2000042034A1 (en) * 1999-01-15 2000-07-20 Byk Gulden Phenanthridine-n-oxides with pde-iv inhibiting activity
NZ512872A (en) 1999-01-15 2003-07-25 Altana Pharma Ag Phenylphenanthridines with PDE-IV inhibiting activity
WO2001035979A2 (en) 1999-11-13 2001-05-25 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
ATE261445T1 (de) 1999-12-08 2004-03-15 Grelan Pharmaceutical Co Neue 1,8-naphtyridin-2(1h)-on-derivate
US6924292B2 (en) * 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
CA2407780A1 (en) 2000-05-25 2001-11-29 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
JP3433752B2 (ja) * 2000-08-11 2003-08-04 小野薬品工業株式会社 ピペリジン誘導体およびその誘導体を有効成分とする薬剤
EP1307183A2 (en) 2000-08-11 2003-05-07 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
EP1353907A2 (en) 2001-01-22 2003-10-22 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
MXPA03006885A (es) * 2001-01-31 2003-11-13 Pfizer Prod Inc Derivados de eteres utiles como agentes inhibidores de las isozimas pde4.
KR20030072614A (ko) * 2001-01-31 2003-09-15 화이자 프로덕츠 인크. Ｐｄｅ４ 이소자임 억제제로 유용한 티아졸릴-,옥사졸릴-, 피롤릴- 및 이미다졸릴-산 아미드 유도체
CZ20032491A3 (cs) 2001-02-15 2004-01-14 Altana Pharma Ag Ftalazinonpiperidinové deriváty
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
AU2003253130A1 (en) 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
WO2004067006A1 (en) 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004098597A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
WO2004098598A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098596A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2004098595A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
MXPA05012302A (es) 2003-05-22 2006-01-30 Altana Pharma Ag Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5.
WO2005020926A2 (en) 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
AU2005248722A1 (en) 2004-04-13 2005-12-08 Arena Pharmaceuticals, Inc. Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders

Also Published As

Publication number Publication date
AU2004269923B2 (en) 2010-05-13
WO2005023253A1 (en) 2005-03-17
JP2007504201A (ja) 2007-03-01
MXPA06002521A (es) 2006-06-20
WO2005023253A8 (en) 2006-03-02
US7776893B2 (en) 2010-08-17
AU2004269923A2 (en) 2005-03-17
US20060281745A1 (en) 2006-12-14
AU2004269923A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
CA2599376C (en) Roflumilast for the treatment of diabetes mellitus
EP1377278B1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
US5478852A (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
CN104013627B (zh) 用于治疗非酒精性脂肪肝疾病的dpp‑iv抑制剂
CA2662084A1 (en) Combination treatment for diabetes mellitus
NO314065B1 (no) Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes
TW200803861A (en) Administration of dipeptidyl peptidase inhibitors
US5708012A (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
CA2236553C (en) Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy
US7776893B2 (en) Use of PDE4 inhibitors for the treatment of diabetes mellitus
JP3007992B2 (ja) （ｒ）−アムロジピンによる平滑筋細胞の遊走の抑制
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
US6710046B1 (en) Pharmaceutical composition for modulating immunity
SK15452001A3 (sk) Farmaceutický prípravok na predchádzanie, liečenie alebo inhibovanie vývoja jednoduchej retinopatie alebo predproliferačnej retinopatie
PL199125B1 (pl) Kompozycja farmaceutyczna zawierająca tiazolidynodion i sulfonylomocznik oraz jej zastosowanie
EP0791355B1 (en) Method of reducing tissue damage associated with ischemia
SK227092A3 (en) Pharmaceutical agent against the high blood pressure
JP4588448B2 (ja) ＰＰＡＲγアゴニストによる治療に伴う体重増加を治療するためのＰＰＡＲαアゴニストの使用
AU2011253752A1 (en) Roflumilast for the treatment of diabetes mellitus
WO2004098606A1 (en) Composition comprising a pde4 inhibitor and shuil-1r ii

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130805